Related Experiment Video
Updated: Jun 5, 2025
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Dual-Multivalent Aptamer-Based Drug Delivery Platform for Targeted SRC Silencing to Enhance Doxorubicin Sensitivity
Haojia Li1, Shuangshuang Cheng1, Qi Zhang1
1Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China.
Abstract:
Endometrial cancer poses a significant threat to women's health. Doxorubicin is commonly used in chemotherapy for advanced and recurrent cases; however, low sensitivity frequently limits its effectiveness. In this study, we verified that SRC modulates the sensitivity of endometrial cancer to chemotherapy of doxorubicin and developed a targeted silencing drug delivery platform that employs rolling circle amplification and dual-multivalent aptamers to precisely deliver therapeutics directly to tumor cells. This platform enhanced endometrial cancer cell sensitivity to doxorubicin by modulating drug responsiveness at the genetic level. Our results suggest that this approach may improve cancer cell susceptibility to ferroptosis. The efficacy and safety of this platform were validated in both cellular and animal models. This study provides a new solution for realizing the precision treatment of endometrial cancer and lays a theoretical foundation for exploring the mechanism of endometrial cancer.
Insights
This study shows SRC impacts endometrial cancer chemotherapy effectiveness. A new targeted drug platform enhances doxorubicin sensitivity, potentially improving treatment outcomes and ferroptosis susceptibility in endometrial cancer.
Area of Science:
- Oncology
- Biotechnology
- Genetics
Background:
- Endometrial cancer is a major women's health concern.
- Doxorubicin chemotherapy is often limited by low cancer cell sensitivity.
- SRC's role in modulating chemotherapy response is not fully understood.
Purpose of the Study:
- To investigate SRC's role in endometrial cancer sensitivity to doxorubicin.
- To develop a targeted drug delivery platform for enhanced chemotherapy.
- To assess the platform's potential to improve ferroptosis susceptibility.
Main Methods:
- Verified SRC's modulation of endometrial cancer sensitivity to doxorubicin.
- Developed a targeted silencing drug delivery platform using rolling circle amplification and dual-multivalent aptamers.
- Validated the platform's efficacy and safety in cellular and animal models.
Main Results:
- The developed platform precisely delivered therapeutics to tumor cells.
- Enhanced endometrial cancer cell sensitivity to doxorubicin by modulating genetic drug responsiveness.
- Demonstrated potential for improved cancer cell susceptibility to ferroptosis.
Conclusions:
- SRC plays a key role in endometrial cancer chemotherapy sensitivity.
- The targeted drug delivery platform offers a novel precision treatment strategy.
- This approach provides a foundation for further research into endometrial cancer mechanisms and treatment.
